Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.
分子癌症治疗学将重点关注对以下领域的癌症治疗有影响的基础研究：实验癌症治疗学、分子靶点的鉴定、化学预防靶点、新模型、癌症化学和药物发现、分子和细胞药理学、肿瘤的分子分类以及生物信息学和计算分子生物学。该杂志为这些新兴学科提供了一个出版论坛，专门关注癌症研究。论文经过严格审查，只有那些报告了新颖、及时和重要研究结果并符合科学价值高标准的论文才会被接受发表。
Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-17-1038
Nanoparticle Delivery of miR-708 Mimetic Impairs Breast Cancer Metastasis
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-18-0702
Metabolic Flexibility in Cancer: Targeting the Pyruvate Dehydrogenase Kinase:Pyruvate Dehydrogenase Axis
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-19-0079
Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-19-0156
MEN1309/OBT076, a First-In-Class Antibody–Drug Conjugate Targeting CD205 in Solid Tumors
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-18-0624
A Simple Three-dimensional Hydrogel Platform Enables Ex Vivo Cell Culture of Patient and PDX Tumors for Assaying Their Response to Clinically Relevant Therapies
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-18-0359
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-18-0976
Inhibition of Sphingosine Phosphate Receptor 1 Signaling Enhances the Efficacy of VEGF Receptor Inhibition
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-18-0548
Mechanisms of Entrectinib Resistance in a Neuroblastoma Xenograft Model
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-18-1044
Ceramide–Rubusoside Nanomicelles, a Potential Therapeutic Approach to Target Cancers Carrying p53 Missense Mutations
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-19-0366
Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-19-0508
Morin Inhibits Proliferation and Induces Apoptosis by Modulating the miR-188-5p/PTEN/AKT Regulatory Pathway in CML Cells
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-19-0051
Reduction of Muscle-Invasive Tumors by Photodynamic Therapy with Tetrahydroporphyrin-Tetratosylat in an Orthotopic Rat Bladder Cancer Model
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-18-1194
GnRH Antagonists Have Direct Inhibitory Effects On Castration-Resistant Prostate Cancer Via Intracrine Androgen and AR-V7 Expression
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-18-1337
Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-18-0048
Genomic Profiling of Blood-Derived Circulating Tumor DNA from Patients with Colorectal Cancer: Implications for Response and Resistance to Targeted Therapeutics
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-18-0965
The Existence of MTH1-independent 8-oxodGTPase Activity in Cancer Cells as a Compensatory Mechanism against On-target Effects of MTH1 Inhibitors
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-19-0437
Abstract B126: A small molecule inhibitor of the RNA m6A writer METTL3 inhibits the development of acute myeloid leukemia (AML) in vivo
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-B126
Abstract B001: Safety and efficacy of ZW25, a HER2-targeted bispecific antibody, in combination with chemotherapy in patients with locally advanced and/or metastatic HER2-expressing gastroesophageal cancer
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.targ-19-b001
Abstract A072: Preliminary results of ASTX660, a novel non-peptidomimetic cIAP1/2 and XIAP antagonist, in 107 patients with solid tumors or lymphoma
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-A072
Abstract B024: Clinical, genomic, and immune landscape of the receptor tyrosine kinase AXL in non-small cell lung cancer
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-B024
Abstract A077: FIGHT-207: Phase 2 study of pemigatinib in patients with previously treated, locally advanced/metastatic or unresectable solid tumor malignancies harboring activating fibroblast growth factor receptor (FGFR) gene alterations
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-A077
Abstract B070: LOCUS database enables rapid query and targeted selection of preclinical tumor models based on cancer genomics and pharmacologic response
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-B070
Abstract B016: CDK7 inhibition suppresses AR addicted Castration-Resistant Prostate Cancer through MED1 inactivation
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-B016
Abstract B052: ATR inhibition potentiates ionizing radiation-induced innate immune response via sensing cytosolic RNAs
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-B052
Abstract A080: Olaparib and the ATR inhibitor AZD6738 in relapsed, refractory cancer patients with homologous recombination (HR) repair mutations – OLAPCO
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-A080
Abstract A038: Assessment of angiogenesis markers in advanced cervical carcinoma patients that received chemoradiation therapy plus/minus neoadjuvant chemotherapy
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-A038
Abstract A120: Adaptive mutability of colorectal cancers in response to targeted therapies
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-A120
Abstract LB-C11: Targeting metastatic prostate cancer with a multi-functional therapy approach
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-LB-C11
Abstract C067: Mechanistic study of the superior anti-cancer properties of a first-in-class small molecule targeting PCNA
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-C067
Abstract A135: Discovery of BGS1954, a covalent small molecule ligand of FABP5 using IMTACTM platform
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.targ-19-a135
Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.MCT-18-1148
Abstract B137: Visualization and quantification of tumor-immune cell interactions in 3D cultures
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-B137
Abstract C064: The investigational peptide drug ALRN-6924, a dual inhibitor of MDMX and MDM2, is an effective myelopreservation agent
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-C064
Abstract LB-C05: The autism and schizophrenia-associated CYFIP1 protein is required for pancreatic tumor growth and presents a potential therapeutic target
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.targ-19-lb-c05
Abstract C059: Inhibition of thymidylate synthase by the ProTide NUC-3373: in vitro analysis and clinical validation
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-C059
Abstract CN09-01: Lessons learnt in clinic from resistance to first generation molecular targeted therapies in solid cancers
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-CN09-01
Abstract LB-A10: ORIC-101 overcomes glucocorticoid-driven resistance to enzalutamide in castration-resistant prostate cancer
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-LB-A10
Abstract KN01: Dissecting antitumor immune response in ovarian cancer
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-KN01
Abstract A012: Mammary fat pad injections: An alternative implantation method for syngeneic tumor models
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-A012
Abstract A034: The use of biomarkers and ctDNA in a phase 1 trial of ARQ 751
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-A034
Abstract LB-C07: Preclinical evaluation of MCLA-129: A bispecific antibody targeting c-MET and EGFR
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-LB-C07
Abstract C117: Development of autologous tumor: TIL coculture from patient-derived samples for in vitro preclinical immuno-oncology studies
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-C117
Abstract C132: Fusobacterium nucleatum in colorectal carcinoma and expression of multiple immune checkpoint molecules on T cells
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-C132
Abstract B009: The histone deacetylase inhibitor pracinostat and its metabolite SB991 are active as single agents and in combination with 5-azacitidine in acute myeloid leukemia cells
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-B009
Abstract C036: Discovery of IACS-13909, an allosteric SHP2 inhibitor that overcomes multiple mechanisms underlying osimertinib resistance
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-C036
Abstract A099: Acoustic Cluster Therapy enhances the efficacy of chemotherapeutic regimens in patient-derived xenograft mouse models for pancreatic ductal adenocarcinoma
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-A099
Abstract LB-B17: Uncovering novel cancer therapeutics using the Exoneural Medicines Platform: The role of innervation in cancer
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-LB-B17
Abstract C120: The tumor suppressor role of STXBP6 in triple negative breast cancer
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.targ-19-c120
Abstract A001: Colorectal cancer cell-derived exosomes containing miR-183-5p regulate angiogenesis via FOXO1
来源期刊：Molecular Cancer TherapeuticsDOI：10.1158/1535-7163.TARG-19-A001
